Roivant Sciences (STU:87S) FFO per Share


STU:87S Roivant Sciences Ltd STU:87S
59 GF Score
Price €31.36
GF Value €9.81
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roivant Sciences FFO per Share?

FFO per Share only applies to REITs.

STU:87S
59GF Score
Roivant Sciences Ltd STU:87S
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Roivant Sciences (STU:87S) Overvalued in 2026?

Based on GuruFocus' analysis, Roivant Sciences stock appears to be overvalued. The current stock price of €31.36 is trading 219.7% above its estimated GF Value™ of €9.81. GuruFocus considers Roivant Sciences to be Significantly Overvalued.

Key valuation signals for STU:87S:

  • FFO per Share:
  • GF Value™: €9.81 vs. price of €31.36 (219.7% above fair value)
  • GF Score™: 59/100 with 7 warning signs

No single metric tells the full story. See the STU:87S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Roivant Sciences Business Description

Other Exchanges ROIV:USA
Address 50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
59GF Score

Get the complete analysis for STU:87S

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€31.36
Price
€9.81
GF Value